Erythrocytes Used as Tumor Antigen Delivery System

Francoise Horand
Published: Monday, May 09, 2016



Françoise Horand, director, R&D Operations, Erytech Pharma, discusses a study investigating the use of erythrocytes as a tumor antigen delivery system to target antigen-presenting cells and induce efficient immune response against tumors.

The innovative approach of Erytech for in situ cancer immunotherapy is to use the property of erythrocytes to be naturally phagocytosed by antigen-presenting cells. Various tumoral antigen can efficiently be loaded into erythrocytes which serve as carrier to specifically deliver the tumor antigen to antigen-presenting cells. Following 2 injections, an efficient and specific immune response is induced, resulting in a significant delay of tumor growth in mouse tumor models of melanoma and prostate cancer.

This new approach of tumor antigen delivery systems to induce immune response can be a very promising strategy in cancer immunotherapy.
SELECTED
LANGUAGE


Françoise Horand, director, R&D Operations, Erytech Pharma, discusses a study investigating the use of erythrocytes as a tumor antigen delivery system to target antigen-presenting cells and induce efficient immune response against tumors.

The innovative approach of Erytech for in situ cancer immunotherapy is to use the property of erythrocytes to be naturally phagocytosed by antigen-presenting cells. Various tumoral antigen can efficiently be loaded into erythrocytes which serve as carrier to specifically deliver the tumor antigen to antigen-presenting cells. Following 2 injections, an efficient and specific immune response is induced, resulting in a significant delay of tumor growth in mouse tumor models of melanoma and prostate cancer.

This new approach of tumor antigen delivery systems to induce immune response can be a very promising strategy in cancer immunotherapy.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Archived Version of a Live Webcast: Virtual Current Trends™: European Perspectives on the Advancing Role of CAR T-Cell Therapy in Hematologic MalignanciesJun 29, 20192.0
Community Practice Connections™: Practical Application of Sequencing for EGFR-Mutant Lung Cancers: A Focus on Recent Evidence and Key Next Steps in TrialsJun 29, 20192.5
Publication Bottom Border
Border Publication
x